Immune responses to adeno-associated virus and its recombinant vectors

Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV-encoded transgenes, raising the potential for their use in vaccine development. In this review, we summarize current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.

[1]  J. Bennett,et al.  A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  S. Forman,et al.  Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. , 1996, Blood.

[3]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[4]  J. Escobedo,et al.  Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. , 1998, Human gene therapy.

[5]  P. Fan,et al.  Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. , 1996, Human gene therapy.

[6]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[7]  J. Lipski,et al.  An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. , 2000, Science.

[8]  S. Kung,et al.  Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. , 1998, Blood.

[9]  R. Samulski,et al.  AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. , 1999, Nature medicine.

[10]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[11]  S. Ponnazhagan,et al.  Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation , 1997, Journal of virology.

[12]  H. Sweeney,et al.  Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. , 2001, Human gene therapy.

[13]  O. Danos,et al.  Successful Interference with Cellular Immune Responses to Immunogenic Proteins Encoded by Recombinant Viral Vectors , 2001, Journal of Virology.

[14]  W. Rascher,et al.  Sustained delivery of therapeutic concentrations of human clotting factor IX – a comparison of adenoviral and AAV vectors administered in utero , 2002, The journal of gene medicine.

[15]  R. Heilbronn,et al.  Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. , 1998, Journal of virological methods.

[16]  D. Russell,et al.  Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2 , 1998, Journal of Virology.

[17]  T. Kezuka,et al.  In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation. , 2000, Investigative ophthalmology & visual science.

[18]  J. Bennett,et al.  Additional transduction events after subretinal readministration of recombinant adeno-associated virus. , 2000, Human gene therapy.

[19]  I. Verma,et al.  Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  P. Beard,et al.  Virus-mediated killing of cells that lack p53 activity , 2001, Nature.

[21]  M. Kay,et al.  Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors , 1999, Nature Medicine.

[22]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Keyun Qing,et al.  Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 , 1999, Nature Medicine.

[24]  James M. Wilson,et al.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Batshaw,et al.  Humoral Immune Response to Recombinant Adenovirus and Adeno-Associated Virus after In Utero Administration of Viral Vectors in Mice , 2002, Pediatric Research.

[26]  Jody A. Vandergriff,et al.  Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV , 2000, Gene Therapy.

[27]  M. Hoggan,et al.  Serologic evidence for human infection with adenovirus-associated viruses. , 1968, Journal of the National Cancer Institute.

[28]  A. Bruce,et al.  Sustained expression of human factor VIII in mice using a parvovirus-based vector. , 2000, Blood.

[29]  F. Marincola,et al.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Schlehofer,et al.  Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.

[31]  R. Herzog,et al.  Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.

[32]  S. Chatterjee,et al.  Adeno-associated virus based vectors as antivirals. , 1996, Current topics in microbiology and immunology.

[33]  C. Walsh,et al.  Induction of tolerance to human factor VIII in mice. , 2001, Blood.

[34]  D. Mohuczy,et al.  Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension. , 1999, American journal of physiology. Heart and circulatory physiology.

[35]  R. Herzog,et al.  Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  James M. Wilson,et al.  Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.

[38]  M. Rocchi,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Takeda,et al.  Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product , 2002, Gene Therapy.

[40]  R. Brady,et al.  Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Dunckley,et al.  Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors , 1998, Gene Therapy.

[42]  G. Deléage,et al.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.

[43]  A. Nienhuis,et al.  Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. , 2001, Blood.

[44]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[45]  Philip R. Johnson,et al.  Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. , 1999, Human gene therapy.

[46]  P. Hermonat,et al.  Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector , 2001, Cancer Gene Therapy.

[47]  A. Beaudet,et al.  Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. , 1999, Human gene therapy.

[48]  G. Dickson,et al.  Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review). , 2000, International journal of molecular medicine.

[49]  James M. Allen,et al.  Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes , 2000, Journal of Virology.

[50]  C. Contag,et al.  In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  P. Hermonat,et al.  Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno‐associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells , 2002, European journal of immunology.

[52]  N. Wong,et al.  Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors , 2002, Journal of Virology.

[53]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[54]  C. Halbert,et al.  Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure , 1998, Journal of Virology.

[55]  Y. Tsao,et al.  Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer , 2000, Journal of Virology.

[56]  J. Bartlett,et al.  Gene therapy: Recombinant adeno-associated virus vectors , 2001, Current cardiology reports.

[57]  T. Flotte,et al.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[58]  H. Mizukami,et al.  A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. , 2001, Human gene therapy.

[59]  B. Byrne,et al.  CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.

[60]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[61]  P. Hermonat,et al.  Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. , 2000, Virology.

[62]  E. Engleman,et al.  Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. , 1999, Clinical immunology.

[63]  A. Gown,et al.  Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Samulski,et al.  αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection , 1999, Nature Medicine.

[65]  J. Schlehofer,et al.  The tumor suppressive properties of adeno-associated viruses. , 1994, Mutation research.

[66]  T. Flotte,et al.  Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. , 1996, Human gene therapy.

[67]  P. Billings In utero gene therapy: The case against , 1999, Nature Medicine.

[68]  H. zur Hausen,et al.  Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. , 1984, Virology.

[69]  R. Samulski,et al.  Adeno-associated viral vectors as gene delivery vehicles. , 2000, International journal of molecular medicine.

[70]  R. Herzog,et al.  Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  N. Chirmule,et al.  CD40 Ligand-Dependent Activation of Cytotoxic T Lymphocytes by Adeno-Associated Virus Vectors In Vivo: Role of Immature Dendritic Cells , 2000, Journal of Virology.

[72]  C. Walker,et al.  Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D , 1997, Journal of virology.

[73]  T. Flotte,et al.  Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.

[74]  J. Mcarthur,et al.  Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. , 2001, Blood.

[75]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[76]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[77]  J. Kaplan,et al.  Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. , 1997, Gene.

[78]  R. Samulski,et al.  Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  P. Laipis,et al.  Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors , 2001, Gene Therapy.

[80]  M. Hallek,et al.  Monoclonal Antibodies against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2–Cell Interaction and Neutralization of AAV-2 Infection , 2000, Journal of Virology.

[81]  O. Danos,et al.  Factors influencing cross‐presentation of non‐self antigens expressed from recombinant adeno‐associated virus vectors , 2001, The journal of gene medicine.

[82]  R. Chanock,et al.  A seroepidemiologic study of adenovirus-associated virus infection in infants and children. , 1971, American journal of epidemiology.

[83]  B. Williams,et al.  Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. , 1997, Experimental hematology.

[84]  A. Srivastava,et al.  Adeno-associated Virus 2-Mediated Transduction and Erythroid Lineage-Restricted Long-Term Expression of the Human β-Globin Gene in Hematopoietic Cells from Homozygous β-Thalassemic Mice , 2001 .

[85]  R. Samulski,et al.  Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.

[86]  James M. Wilson,et al.  Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.

[87]  J. Wilson,et al.  Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  De-Pei Liu,et al.  Hot topics in adeno-associated virus as a gene transfer vector , 2001, Molecular biotechnology.

[89]  J. Mcarthur,et al.  Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure , 2000, Journal of Virology.

[90]  R. Samulski,et al.  Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.

[91]  T. Griffith,et al.  The immune response and the eye. TCR alpha-chain related molecules regulate the systemic immunity to antigen presented in the eye. , 1995, International immunology.

[92]  J. Bartlett,et al.  Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. , 2001, Human gene therapy.

[93]  T. Flotte,et al.  Repeated Delivery of Adeno-Associated Virus Vectors to the Rabbit Airway , 1999, Journal of Virology.

[94]  K. Qing,et al.  Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[95]  J. Rosenblatt,et al.  Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes , 1994, Molecular and cellular biology.

[96]  S. Forman,et al.  Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. , 2002, Cancer research.

[97]  G. Deléage,et al.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.

[98]  G. Podsakoff,et al.  Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors , 1994, Journal of virology.

[99]  Wei Li,et al.  Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. , 1999, Blood.

[100]  K. High,et al.  Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice , 2001, Gene Therapy.

[101]  H. Ertl,et al.  Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[102]  G. Stamatoyannopoulos,et al.  A High-Capacity, Capsid-Modified Hybrid Adenovirus/Adeno-Associated Virus Vector for Stable Transduction of Human Hematopoietic Cells , 2002, Journal of Virology.

[103]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.

[104]  Lili Wang,et al.  Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer , 2001, Journal of Virology.

[105]  J. Kleinschmidt,et al.  Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins , 1997, Journal of virology.

[106]  F. Wolber,et al.  Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. , 2002, Blood.

[107]  James M. Wilson,et al.  Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers , 1998, Journal of Virology.

[108]  C. Giraud,et al.  Biology of adeno-associated virus. , 1996, Current topics in microbiology and immunology.

[109]  M. S. Chapman,et al.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.